24-Month Registry Results on Drug-Coated Balloon Angioplasty Below the Knee: Strong Enough Evidence to Convince the Scep
- PDF / 179,929 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 37 Downloads / 144 Views
COMMENTARY
COMMENTARY
24-Month Registry Results on Drug-Coated Balloon Angioplasty Below the Knee: Strong Enough Evidence to Convince the Sceptics? Ulf Teichgra¨ber1
Received: 14 July 2020 / Accepted: 4 August 2020 The Author(s) 2020
Critical limb ischemia (CLI) requires immediate revascularization to prevent limb loss. In less-complex disease and in patients with severe comorbidities, the endovascular approach can be the preferred strategy. However, so far, research on Paclitaxel drug-coated balloon (DCB) angioplasty of below-the-knee (BTK) arteries gives rise to controversy. Initially, the single-center DEBATE-BTK study (65 DCB vs. 67 POBA participants) suggested a potential advantage of DCB angioplasty over standard balloon angioplasty (plain old balloon angioplasty; POBA) [1]. DCB significantly reduced the incidence of 12-month binary restenosis and target lesion revascularization (TLR). No major amputation was needed. In contrast, the larger, multi-center IN.PACT DEEP trial that evaluated the same DCB (IN.PACT Amphirion) failed to meet superiority of DCB over POBA and showed only comparable 5-year effectiveness (follow-up completed in 95 DCB and 49 POBA participants). The tendency to an increased rate of major amputations with DCB angioplasty at 12 months weakened throughout 5-years (15.4% DCB vs. 10.6% POBA; p = 0.11) [2]. The randomized BIOLUX P-II trial (36 DCB vs. 36 POBA participants) presented 12-month results on the Passeo-18 BIOLUX DCB and also confirmed only comparable effectiveness between DCB and POBA without any safety signal from DCB (major amputation: DCB 3.3% vs. POBA 5.6%; p = 0.63) [3]. Finally, 12-month outcomes from the APOLLO observational study on the ELUTAX SV DCB in CLI patients (164 & Ulf Teichgra¨ber [email protected] 1
Department of Radiology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany
participants) revealed estimates of primary patency and freedom from TLR of 68.5% and 90.6%, respectively. Incidence of major amputation and mortality was 5% and 15.9%, respectively [4]. In this issue of CVIR, Tepe et al. present 24-month results of DCB angioplasty in a pre-specified subgroup of 151 participants with BTK lesions from the real-world BIOLOUX P-III registry [5]. Most of the participants had CLI (76.0%) with a share of 22.3% categorized as Rutherford-Becker class 6. A total of 62.9% participants were diabetics. Mean lesion length was 7.9 cm, proportionate share of total occlusions 18.4%, and that of severely calcified lesions 9.8%. Lesion preparation was conducted in 73.0% and bailout stenting in 1.1% of lesions. No data are provided whether inflow vessels were diseased or treated. At 24 months, primary patency and freedom from TLR were favorable (82.8% and 90.9%, respectively), however, against the background of 9.9% major amputations and 20.8% mortality. Overall, Tepe et al. provided valuable data on effectiveness of DCB, however, no direct comparison with POBA, the standard of care, which would be needed to prove efficacy. The range of 12-month ef
Data Loading...
